Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential NTHi-Mcat vaccine after Shingrix in healthy smokers and ex-smokers
2018-002977-24Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2019
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of GSK3277511A and Zoster vaccine recombinant in chronic obstructive pulmonary disease (COPD), bacterial airway infections and herpes zoster (HZ) (4 arms), sponsored by GSK. Primary endpoints: Anti-PD antibody geometric mean concentration, Anti-PE antibody geometric mean concentration and 2 more. Started Jan 2019; status: completed.
02
Drugs
GSK3277511AZoster vaccine recombinant
03
Conditions
chronic obstructive pulmonary disease (COPD)bacterial airway infectionsherpes zoster (HZ)
Beyond the preview
Go deeper on 2018-002977-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002977-24.